Yanqiu Liu

• Advised Wuhan Youji Holdings Ltd. in its global offering and IPO on the Hong Kong Stock Exchange.
• Advised GenScript Biotech, a biotechnology company focused on gene synthesis technology, and its indirect wholly-owned subsidiary Probio Technology in Probio Technology’s series financing, with an aggregate investment amount exceeding $400 million.
• Advised De Well, an international logistics company, on the subscription of its equity interest by an investing vehicle of Cainiao, a global logistics service provider under Alibaba Group.
• Advised Fosun Tourism Group in its $428 million global offering and IPO on the Hong Kong Stock Exchange.

Private Equity / M&A

• Advised Big Tree Cloud International Group Limited, a company devoted to the development, production and sales of personal care products and other consumer goods in China, in its $500 million merger with special purpose acquisition company Plutonian Acquisition Corp., and subsequent listing on the NASDAQ.
• Advised De Well, an international logistics company, on the subscription of its equity interest by an investing vehicle of Cainiao, a global logistics service provider under Alibaba Group.
• Advised GenScript Biotech, a biotechnology company focused on gene synthesis technology, and its indirect wholly-owned subsidiary Probio Technology in:

- a Series A financing transaction from private equity firm Hillhouse Capital, which subscribed minority equity interest in Probio Technology for $150 million, with a $125 million warrant to purchase additional shares;

- its $37 million Series B financing from Zhenjiang High-Tech Venture Capital; and

- its Series C financing, with investments from Legend Capital, Highlight Capital, Hillhouse Capital and other prominent institutional investors. Probio Technology raised approximately $224 million from the Series C investors.

• Advised Apex Group’s founder shareholders in their equity sales transaction as part of the Swiss publicly listed company Kuehne+Nagel’s acquisition of the Apex Group, a leading logistics company.
• Advised YF Capital, a leading private equity firm in China, in its RMB100 million investment in a PRC semiconductor manufacturer.
• Advised American International Group to dispose its equity interest in a sino-foreign cooperative joint venture established in the mid-1980s, which owns Shanghai Centre, a landmark building in downtown Shanghai.

Capital Markets

• Advised SinoMab BioScience Limited in its $176.5 million global offering and IPO on the Hong Kong Stock Exchange as a Chapter 18A biotech company.
• Advised Fosun Tourism Group in its $428 million global offering and IPO on the Hong Kong Stock Exchange.
• Advised Jiangsu Dieshiqiao Home Textile Industry Group, a Chinese state-owned property leasing, infrastructure and resettlement housing construction enterprise, in its issuance of $100 million 2.2% credit enhanced bonds due 2024.
• Advised AMC Wanhai Securities, Haitong International, Shanghai Pudong Development Bank, China Galaxy International Securities, CMBC Securities, Industrial Bank and Guoyuan Capital as the joint lead managers in the issuance of $150 million 2.8% credit enhanced bonds due 2024 by Rudong County Jinxin Transportation Engineering Construction Investment Co., Ltd., a Chinese state-owned infrastructure investment company.
• Advised Mei Nian Investment and Meinian Onehealth as the issuer and parent guarantor respectively on Mei Nian Investment’s issuance of $200 million guaranteed senior notes due 2021. Meinian Onehealth is one of the largest private health checkup services providers in China.

Other Corporate Matters

• Advised one of the largest integrated shipping companies in China on CFIUS-related matters with respect to its substantial acquisition.
• Advised several U.S. and European companies in their general corporate matters.

Dispute Resolution

• Advised a PRC-based private equity fund in HKIAC arbitration in disputes arising from acquisition of a PRC subsidiary from a US-listed company.
• Advised a US-based private equity fund in HKIAC arbitration in disputes arising from real estate joint ventures in China, and coordinated strategy for parallel proceedings in CIETAC.